Lake Street lowered the firm’s price target on Rapid Micro Biosystems (RPID) to $7 from $8 and keeps a Buy rating on the shares after the company announced an underwritten public offering and concurrent registered direct offering with upfront gross proceeds of about $9.8M and potential additional gross proceeds of about $21.7M if the accompanying warrants are exercised in cash. The firm lowered its price target to reflect the increase in share count resulting from the financing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPID:
- Rapid Micro Biosystems Announces Underwritten Equity and Warrant Offering
- Rapid Micro Biosystems Earnings Call Balances Growth And Risk
- Rapid Micro Biosystems reports Q1 EPS (31c), consensus (25c)
- Rapid Micro reaffirms FY26 revenue outlook of $37M-$41M, consensus $39.23M
- Is RPID a Buy, Before Earnings?